ERBB2 and breast cancer: Pertuzumab, an anti-HER2 monoclonal antibody that binds to another domain of HER2 than trastuzumab, has been demonstrated to improve survival when it was added to treatment with trastuzumab and chemotherapy in breast cancer patients [17, 18].